Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Pfizer, Inc.
PFE
$28.19
Name : Pfizer, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $160,326,320,128.00
EPSttm : 1.36
finviz dynamic chart for PFE
Pfizer, Inc.
$28.19
0.37%
$0.105
PFE — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2.31

Margin Of Safety %

27

Put/Call OI Ratio

0.82

EPS Next Q Diff

0.04

EPS Last/This Y

1.59

EPS This/Next Y

-0.14

Price

28.08

Target Price

28.52

Analyst Recom

2.59

Performance Q

12.32

Upside

-37.0%

Beta

0.38

Ticker: PFE




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-02PFE27.240.840.872584827
2026-03-04PFE26.590.841.202627029
2026-03-05PFE26.60.820.552633006
2026-03-09PFE26.810.780.482676651
2026-03-10PFE27.160.780.342694299
2026-03-11PFE27.290.780.582725336
2026-03-12PFE26.850.781.582746740
2026-03-17PFE27.480.780.642726401
2026-03-18PFE27.330.791.532782467
2026-03-19PFE27.450.820.372856748
2026-03-20PFE26.980.820.572879679
2026-03-23PFE26.790.860.842265318
2026-03-24PFE26.990.860.372318873
2026-03-25PFE27.310.860.272358980
2026-03-26PFE27.560.840.342390608
2026-03-27PFE27.040.840.612423188
2026-03-30PFE27.760.830.592318141
2026-03-31PFE28.010.820.262370853
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02PFE27.23-21.07899.12.96
2026-03-03PFE26.60-20.97760.92.96
2026-03-04PFE26.59-20.98140.02.96
2026-03-05PFE26.59-20.97670.02.96
2026-03-06PFE27.04-20.97940.62.96
2026-03-09PFE26.81-20.99660.52.96
2026-03-10PFE27.16-20.99990.22.96
2026-03-11PFE27.30-20.99871.92.96
2026-03-12PFE26.86-20.912655.02.96
2026-03-13PFE26.60-20.99648.72.96
2026-03-17PFE27.48-20.910281.52.96
2026-03-18PFE27.33-20.99728.12.96
2026-03-19PFE27.42-20.98752.72.96
2026-03-20PFE26.99-20.98479.12.96
2026-03-23PFE26.78-20.98597.72.96
2026-03-24PFE26.96-20.98798.62.96
2026-03-25PFE27.31-20.98882.52.96
2026-03-26PFE27.56-20.98844.42.96
2026-03-27PFE27.03-20.98420.42.96
2026-03-30PFE27.76-20.99076.82.96
2026-03-31PFE28.08-20.98857.82.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02PFE0.000.332.58
2026-03-03PFE0.000.332.58
2026-03-04PFE0.000.332.58
2026-03-05PFE0.000.332.58
2026-03-06PFE0.000.332.58
2026-03-09PFE0.000.282.58
2026-03-10PFE0.000.282.58
2026-03-11PFE0.000.282.51
2026-03-12PFE0.000.282.51
2026-03-13PFE0.000.282.51
2026-03-17PFE0.000.252.51
2026-03-18PFE0.000.252.51
2026-03-19PFE0.000.252.51
2026-03-20PFE0.000.252.51
2026-03-23PFE0.000.242.51
2026-03-24PFE0.000.242.51
2026-03-25PFE0.000.242.31
2026-03-26PFE0.000.242.31
2026-03-27PFE0.000.242.31
2026-03-30PFE0.000.252.31
2026-03-31PFE0.000.252.31
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

0.66

Avg. EPS Est. Current Quarter

0.73

Avg. EPS Est. Next Quarter

0.7

Insider Transactions

Institutional Transactions

0.25

Beta

0.38

Average Sales Estimate Current Quarter

13905

Average Sales Estimate Next Quarter

14490

Fair Value

35.57

Quality Score

80

Growth Score

48

Sentiment Score

98

Actual DrawDown %

54.5

Max Drawdown 5-Year %

-59

Target Price

28.52

P/E

20.72

Forward P/E

9.96

PEG

P/S

2.55

P/B

1.85

P/Free Cash Flow

17.59

EPS

1.36

Average EPS Est. Cur. Y​

2.96

EPS Next Y. (Est.)

2.82

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.38

Relative Volume

0.98

Return on Equity vs Sector %

-18.4

Return on Equity vs Industry %

-27.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

8857.8
PFE Healthcare
$28.08
📉
Swing / Pullback
Buy the dip on strong trends
50 /100
WEAK
Trend
20/20
Pullback
8/25
Volume
7/15
Valuation
11/20
TP/AR
0/10
Options
4/10
RSI
61
Range 1M
85.3%
Sup Dist
2.6%
🚀
Momentum Growth
Ride accelerating trends
N/A
33 /100
WEAK
Momentum
14/25
Growth
2/30
Estimates
4/20
Inst/Vol
6/15
Options
7/10
EPS Yr
-8.2%
EPS NY
-4.6%
52W%
95.8%
💎
Long-Term Value
Quality companies, undervalued
36 /100
WEAK
🟡 HOLD +23.6% upside
Quality
10/30
Valuation
15/30
Growth
3/25
Stability
4/10
LT Trend
4/5
Upside
+23.6%
Quality
80
MoS
27%
Pfizer, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE

Latest News

Caricamento notizie per PFE
stock quote shares PFE – Pfizer Inc. Stock Price stock today
news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PFE – Pfizer Inc. yahoo finance google finance
stock history PFE – Pfizer Inc. invest stock market
stock prices PFE premarket after hours
ticker PFE fair value insiders trading